Testosterone gel trial aims to beat cancer fatigue in older men

NCT ID NCT04301765

Ongoing Symptom relief Sponsor: Seattle Institute for Biomedical and Clinical Research Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will measure changes in fatigue and sexual activity using standard questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: testosterone gel
What this could lead to: If it works, this could offer a way to ease fatigue and improve sexual health in older men with cancer who have low testosterone.
What could go wrong: This is a phase 2 trial, so results are still uncertain. Testosterone may not help fatigue, and there are risks like worsening prostate cancer or heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer eunuchism Fatigue hematopoietic and lymphoid cell neoplasm hypogonadism hypogonadism, male neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER FATIGUE HYPOGONADISM, MALE

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Georgia Cancer Center at Augusta University

Augusta, Georgia, 30912, United States
Veterans Affairs Puget Sound Health Care System

Seattle, Washington, 98108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.